Shattuck Labs, Inc. (STTK)

Over the past six months, Shattuck Labs' stock has experienced a significant price increase, with the share price as of January 2, 2026, representing a 176.87% increase from January 3, 2025. Analysts upgraded Shattuck Labs in December 2025, with one firm initiating coverage with an "Outperform" rating and a $4 price target. Shattuck Labs reported its Q3 2025 financial results and business highlights on November 6, 2025, and participated in investor conferences in December 2025. On December 15, 2025, Shattuck Labs announced inducement equity awards to a newly-hired non-executive officer. In August 2025, Shattuck Labs closed a private funding round, raising up to $103 million, which is expected to fund operations through 2029. The company submitted an Investigational New Drug (IND) application for SL-325 for IBD treatment, with FDA clearance expected in Q3 2025, and the Phase 1 clinical trial in healthy volunteers was set to begin in Q3 2025. Shattuck Labs decided to discontinue its clinical program for SL-172154 after interim data showed only modest improvements in overall survival for patients with TP53 mutant AML and higher-risk MDS, shifting its focus to SL-325.

Information directly detailing the demand seasonality for Shattuck Labs, Inc.'s products and services is not explicitly available in the provided search results, however, an analysis of the stock's seasonal chart over the past four years suggests a seasonal strength for STTK shares with a "Buy Date" of November 10 and a "Sell Date" of January 31. This period has shown a geometric average return of 77.64% above the S&P 500 Total Return Index. It is important to note that only four years of stock data are available, which may be insufficient for a reliable seasonal analysis of the stock, and this does not directly reflect the seasonality of demand for its pharmaceutical products. The company operates in the biotechnology industry, where product demand is typically driven by disease prevalence, clinical trial outcomes, regulatory approvals, and market adoption of new therapies, rather than traditional seasonal consumer patterns.

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and immune-mediated diseases, operating within the healthcare sector, specifically in the biotechnology and pharmaceutical preparations industry, with expertise in protein engineering and the development of novel TNF receptor therapeutics. The company's lead product candidate is SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete and durable blockade of the clinically validated DR3/TL1A pathway, targeting inflammatory bowel disease (IBD) and other inflammatory and immune-mediated conditions. Shattuck Labs is also developing SL-425, a half-life extended version of SL-325, and advancing multiple preclinical DR3-based bispecific antibodies aimed at inhibiting both the DR3/TL1A axis and other biologically relevant targets for IBD treatment, as well as the preclinical development of lead TRIM7 inhibitors as future internal pipeline candidates in oncology.

Shattuck Labs, Inc. has research and development (R&D) facilities located in Durham, North Carolina, and its corporate office is situated in Austin, Texas.

Shattuck Labs' brand reputation in the past year appears to be largely influenced by its clinical development progress and financial activities, with positive events including analyst upgrades and price target increases, a successful private placement, and the advancement of SL-325. A notable event that could have impacted its reputation was the discontinuation of the SL-172154 clinical program in favor of focusing on SL-325 due to modest clinical benefits, which might be seen as a setback for one program, but the company's clear pivot to a more promising candidate could also be viewed positively by the market.

Individual investors represent the largest ownership group in Shattuck Labs, holding a 32% stake, while insiders own 10% of the company, with CEO Taylor Schreiber owning 4.3% of the shares, and hedge funds collectively own 27% of Shattuck Labs. Major institutional owners include Orbimed Advisors Llc, Adage Capital Partners Gp, L.l.c., Redmile Group, LLC, Prosight Management, LP, Vanguard Group Inc, 683 Capital Management, LLC, Clark Estates Inc/ny, Pinnacle Associates Ltd, Bank Of America Corp /de/, and Millennium Management LLC.